Three-dimensional dose model for the comparison of 177Lu-HuCC49DeltaCH2 and 177Lu-HuCC49 radioimunotherapy in mice bearing intraperitoneal xenografts.
Uptake and dose distributions in peritoneal LS174T colon tumor xenografts were compared for a humanized construct of the CC49 (HuCC49) high-affinity anti-TAG-72 monoclonal antibody and a construct with the CH2 region deleted (HuCC49DeltaCH2), both labeled with (177)Lu using a PA-DOTA bifunctional chelating agent and injected in the peritoneum. Tumors were resected and serially sectioned at 1 h, 4 h, 24 h, and 48 h postinjection. Between 5 and 24 (average 16) sections were retained per tumor for autoradiography. The typical section interval was 340 microm and thickness was 16 microm. Tumor sections were air dried and placed on film and/or phosphor screen. Section images were digitized at 100 microm resolution electronically (phosphor screen) or by laser densitometer (film). Section images were used to generate tumor surface descriptions and activity distributions by reconstructing the activity densities in three dimensions. Three-dimensional dose-rate calculations, performed using a point kernel for (177)Lu, were used to prepare radial histograms describing the variation in dose rate as a function of distance from the tumor center to surface. At early times postinjection, the (177)Lu-HuCC49DeltaCH2 antibody displayed higher dose rates near the tumor surface compared to the (177)Lu-HuCC49 antibody. At 24 h postinjection, dose rate distributions appeared similar for both antibodies and more uniform than at earlier times. The (177)Lu-HuCC49DeltaCH2 antibody indicated improved uniformity at 48 h postinjection. Cell survival calculations based on the three-dimensional dose rate distributions favored (177)Lu-HuCC49DeltaCH2 for equal injection activities. However the most significant effect was the greater injected dose tolerated for the (177)Lu-HuCC49DeltaCH2 antibody based on equivalent estimated bone marrow dose.
Roberson
Peter L
PL
University of Michigan, Ann Arbor 48109, USA. roberpl@umich.edu
Yokoyama
Shigeru
S
Rogers
Buck E
BE
Buchsbaum
Donald J
DJ
D000814:Aniline Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000818:Animals; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D006571:Heterocyclic Compounds / Q000493:pharmacokinetics* / Q000627:therapeutic use; D006801:Humans; D008187:Lutetium / Q000493:pharmacokinetics* / Q000627:therapeutic use; D051379:Mice; D008819:Mice, Nude; D008954:Models, Biological; D009374:Neoplasms, Experimental / Q000378:metabolism / Q000532:radiotherapy; D010534:Peritoneal Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary; D016499:Radioimmunotherapy; D011879:Radiotherapy Dosage; D014018:Tissue Distribution; D014183:Transplantation, Heterologous
D000814:Aniline Compounds; D000911:Antibodies, Monoclonal; D006571:Heterocyclic Compounds; C085738:4-aminophenylethyl-1,4,7,10-tetraazacyclodecane-N,N',N'',N'''-tetraacetic acid; D008187:Lutetium